Published in Cancer Weekly, February 24th, 2004
As provided under the patent licensing master agreement between the companies, Genentech and PDL each may obtain non-exclusive licenses under certain of the other company's patents or applications subject to certain conditions including payment of a license fee of up to approximately $1 million per antibody.
Mark McDade, chief executive officer, PDL, said, "The two new Genentech licenses increases to six the number of marketed humanized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly